-
ALS Stem Cell Therapy: Too Soon to Tell
NSI-566/ALS Principal Investigator, Dr. Eva Feldman’s, presentation of Phase I data at the American Neurological Association annual meeting, is reported in this article which cites the three of 15 Phase I patients “receiving the most extensive injections showed stabilization of functional scores after almost 2 years of follow-up.”
Select media coverage in this website is provided for the information and convenience of the public, and is not intended to be all-encompassing nor an endorsement of the specific stories or media outlets.